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dissemination via its induction of P-cadherin
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Background: Epithelial ovarian cancer (EOC) is a lethal disease that frequently involves the peritoneal cavity.
Dissemination of EOC is a multi-step process in which exfoliated tumor cells survive in the peritoneal fluid as
multi-cellular aggregates and then form invasive implants on peritoneal surfaces. The mechanisms that control this
process are poorly understood. We previously identified that high expression of the developmental patterning
gene HOXA9 is associated with poor survival in EOC patients. In this study, we investigated the significance and
mechanisms of HOXA9 in controlling aggregation and implantation of floating EOC cells.
Methods: HOXA9 was inhibited by shRNAs or expressed in EOC cells that were propagated in suspension cultures
and in the peritoneal cavity of mice. Cell death was assayed by flow cytometry and ELISA. Cell aggregation,
attachment and migration were evaluated by microscopy, transwell chamber assays and histopathologic analysis.
DNA-binding of HOXA9 and its effect on expression of the cell adhesion molecule P-cadherin were assayed by
chromatin immunoprecipitation, quantitative RT-PCR and Western blot. HOXA9 and P-cadherin expression was
evaluated in publicly available datasets of EOC clinical specimens.
Results: We identified that HOXA9 promotes aggregation and inhibits anoikis in floating EOC cells in vitro and in
xenograft models. HOXA9 also stimulated the ability of EOC cells to attach to peritoneal cells and to migrate.
HOXA9 bound the promoter of the CDH3 gene that encodes P-cadherin, induced CDH3 expression in EOC cells,
and was associated with increased CDH3 expression in clinical specimens of EOC. Inhibiting P-cadherin in EOC
cells that expressed HOXA9 abrogated the stimulatory effects of HOXA9 on cell aggregation, implantation and
migration. Conversely, these stimulatory effects of HOXA9 were restored when P-cadherin was reconstituted in
EOC cells in which HOXA9 was inhibited.
Conclusion: These findings indicate that HOXA9 contributes to poor outcomes in EOC in part by promoting
intraperitoneal dissemination via its induction of P-cadherin.
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More than 60% of women with epithelial ovarian can-
cer (EOC) are diagnosed with advanced-stage disease
that has disseminated throughout the peritoneal cavity
[1]. Despite advances in tumor debulking surgery and
chemotherapy, patients with advanced-stage EOC have
a 5-year survival rate of only 30% [1]. Whereas many other
types of solid tumors metastasize via hematogenous or* Correspondence: hnaora@mdanderson.org
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ding into the peritoneal fluid which transports tumor
cells, either as multi-cellular aggregates or as single
cells, throughout the peritoneal cavity [2-4]. Subse-
quently, EOC cells attach to the mesothelium-lined
peritoneal surfaces, such as the cavity wall, diaphragm
and omentum, where they form invasive implants [2-4].
This ‘seeding’ of the peritoneal cavity with tumor cells is
often associated with ascites formation. Although it is
unclear whether EOC cells detach from the primary
tumor as clusters or as single cells that then assemblel Ltd. This is an Open Access article distributed under the terms of the Creative
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cells are increasingly regarded as ‘seeds of metastasis’
that are able to escape anoikis and implant on to
peritoneal surfaces [3-5]. However, the tissue-specific
mechanisms that facilitate the aggregation and implant-
ation of floating EOC cells and drive the unique clinical
behavior of this disease are poorly understood.
Homeobox genes encode transcription factors, com-
monly termed homeoproteins, that play essential roles in
controlling developmental patterning and are expressed
in a tightly regulated temporal and tissue-specific man-
ner [6-8]. Many homeoproteins are aberrantly expressed
in a variety of malignancies, but their functional signifi-
cance in tumor progression is poorly understood as only
few bona fide target genes have been identified [6,7].
The homeobox gene HOXA9 is normally expressed
during differentiation of the Müllerian ducts into the
female reproductive tract [9]. We have identified that
high HOXA9 expression is strongly associated with
poor overall survival of EOC patients [10]. Studies of
mouse xenograft models revealed that expression of
HOXA9 in EOC cells promotes growth of solid peri-
toneal implants by inducing normal peritoneal fibro-
blasts and mesenchymal stem cells to acquire features
of cancer-associated fibroblasts that in turn supported
tumor growth and angiogenesis [10]. This stimulatory
effect of HOXA9 on solid tumor growth was attributed
to its activation of the gene encoding transforming
growth factor-β2 (TGF-β2) that acted in a paracrine
manner on stromal cells [10]. Because EOC cells in
solid tumors and in ascites have different biological
behaviors and exist in different microenvironments, we
investigated the possibility that HOXA9 mediates other
types of effects in free-floating EOC cells. In this study,
we identified that HOXA9 promotes the assembly of
floating EOC cells into multi-cellular aggregates and
inhibits anoikis, and also stimulates tumor-peritoneum
interactions and tumor cell migration. These stimula-
tory effects of HOXA9 were found to be largely attrib-
utable to its induction of the cell adhesion molecule
P-cadherin that is encoded by the CDH3 gene, a tran-
scriptional target of HOXA9.
Results
HOXA9 promotes aggregation and survival of floating
EOC cells in i.p. xenograft models
We previously identified that expression of HOXA9 in
EOC cells promotes growth of solid tumor xenografts,
but does not stimulate proliferation of EOC cells in vitro
[10]. Because the biological behavior of ascitic tumor
cells markedly differs from that of solid tumors, we
investigated the effect of HOXA9 on floating EOC cells
in ascites. I.p. xenograft models were generated from
previously established HOXA9+ control and HOXA9shRNA-expressing SKOV3ip cell lines [10]. These EOC
cell lines stably expressed GFP, enabling their detection
among host cells in ascites. Floating EOC cells in asci-
tes of control xenograft models (that expressed empty
vector or non-targeting shRNA) were present as large
compact aggregates [Figure 1A]. In contrast, ascites
collected from HOXA9-knockdown models (shA9-A,
shA9-B) contained smaller aggregates or single EOC
cells [Figure 1A]. The aggregation of floating EOC cells
is thought to enable these cells to escape anoikis [3,4].
Cell death was evaluated within the population of
GFP-expressing ascitic EOC cells by flow cytometric
analysis of 7-amino actinomycin D (7AAD) staining.
As shown in Figure 1B, the proportion of ascitic EOC
cells that exhibited cell death was substantially higher
in the HOXA9-knockdown models than in control
models. These observations raise the possibility that
HOXA9 promotes aggregation of floating EOC cells
and inhibits anoikis.
HOXA9 also increases EOC cell implantation and
invasiveness
Floating EOC cells that are transported by the peritoneal
fluid frequently implant on the diaphragm, peritoneal
cavity wall, omentum and mesentery [2-4]. We evalu-
ated sections of tissues collected from mice that were
inoculated with equivalent numbers of control and
HOXA9-knockdown SKOV3ip cells. Whereas numer-
ous mesenteric implants were detected in the control
groups, fewer implants were detected in the HOXA9-
knockdown groups [Figure 1C]. In EOC patients, implants
tend to only invade the superficial bowel serosa and
not the deeper layers [3]. Some superficial bowel serosa
invasion was observed in control mice, but was markedly
reduced in the HOXA9-knockdown groups (P < 0.05)
[Additional file 1: Figure S1A]. Implants on the dia-
phragm extensively invaded adjacent muscle in the control
groups, whereas invasive depth of diaphragmatic implants
was significantly reduced in the HOXA9-knockdown
groups (P < 0.01) [Figure 1D; Additional file 1: Figure S1B].
Similarly, implants on the peritoneal cavity wall were
significantly less invasive in the HOXA9-knockdown
groups than in the control groups (P < 0.01) [Additional
file 1: Figure S1C]. These findings indicate that HOXA9
not only promotes aggregation and survival of floating
EOC cells, but also increases the peritoneal implant-
ation and invasiveness of these cells.
HOXA9 promotes aggregation and inhibits anoikis of EOC
cells in vitro
The development of tumor implants at distal sites
depends on the survival of free-floating EOC cells that
escape anoikis by forming multi-cellular aggregates [3,4].
We investigated the possibility that HOXA9 promotes
Figure 1 Knockdown of HOXA9 inhibits aggregation and survival of ascitic EOC cells and decreases EOC cell implantation and
invasiveness in i.p. xenograft models. Female nude mice (n = 5 per group) were inoculated i.p. with equivalent numbers (2 × 106) of
GFP-expressing HOXA9+ control (empty vector, non-targeting) and HOXA9-knockdown (shA9-A, shA9-B) SKOV3ip cells. Mice were sacrificed
at 3 weeks thereafter. (A,B) Ascitic cells were collected and stained with Hoechst dye to visualize nuclei and with 7AAD to assay cell death.
(A) Representative examples of Hoechst staining (shown in blue) of ascitic cells where GFP-expressing tumor cells (shown in green) were
visualized by fluorescence microscopy. Bar, 50 μm. (B) Flow cytometric analysis of 7AAD staining within the gated population of GFP + ascitic tumor
cells. (C,D) Representative examples of HE-stained sections of (C) bowel tissues with mesenteric implants (bar, 1 mm) and (D) diaphragmatic
implants (bar, 100 μm).
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assays, independently of implantation and of effects of
host cells. Cells of control and HOXA9-knockdown
SKOV3ip lines were incubated as suspension cultures
in plates coated with poly(2-hydroxyethyl methacrylate)
(polyHEMA), an inert polymer that prevent cells
from adhering to substratum. Whereas control cells
formed large aggregates, suspension cultures of HOXA9-
knockdown cells comprised of single cells and smallaggregates of loosely clustered cells [Figure 2A]. Cell
death was observed in HOXA9-knockdown cells as
detected by staining with 7AAD [Figure 2B]. In contrast,
control cells were mostly viable [Figure 2B]. Evaluation of
active caspase 3 levels indicated higher levels of apoptotic
cell death in HOXA9-knockdown cells than in control
cells [Figure 2C]. The increased level of cell death in
HOXA9-knockdown cells was additionally confirmed by
assaying mono- and oligo- nucleosomes in cell lysates
Figure 2 Knockdown of HOXA9 inhibits aggregation of floating EOC cells, increases anoikis, decreases EOC-mesothelial cell interactions,
and reduces EOC cell migration in vitro. (A-D) Cells of control and HOXA9-knockdown SKOV3ip lines were incubated as suspension cultures in
polyHEMA-coated plates for 3 days and evaluated for changes in cell morphology and cell death. (A) Cell morphology viewed by phase-contrast
light microscopy. Bar, 100 μm. The extent of cell death was evaluated by flow cytometric analysis of (B) 7AAD staining and (C) staining of
active caspase-3. In (D), cell death was evaluated by assaying mono- and oligo- nucleosomes in cell lysates by ELISA. Shown are mean ± sd
values of three independent experiments. Significance of differences was evaluated by Student t-test. (E,F) Equivalent numbers of control
and HOXA9-knockdown SKOV3ip cells that stably expressed GFP were seeded onto confluent monolayers of normal human omental mesothelial cells.
At 1 h thereafter, attached tumor cells were viewed by fluorescence microscopy and counted in three random 100× microscopic fields per assay.
(E) Representative examples of SKOV3ip cells (shown in green) attached to mesothelial monolayers. Bar, 100 μm. (F) Mean ± sd values of
three independent attachment assays. (G) Equivalent numbers of control and HOXA9-knockdown SKOV3ip cells were seeded in transwell
chambers. At 6 h thereafter, migrating cells were counted in three random 100x microscopic fields per assay. Shown are mean ± sd values
of three independent migration assays.
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HOXA9 promotes the assembly of floating EOC cells
into multi-cellular aggregates and inhibits anoikis.
HOXA9 stimulates interactions between EOC cells and
peritoneal mesothelial cells and promotes EOC cell
migration in vitro
In subsequent experiments, we performed short-term
in vitro attachment assays to evaluate the effect of
HOXA9 on interactions between EOC cells and peri-
toneal mesothelial cells independently of its effects on
aggregation and survival of EOC cells. Equivalent num-
bers of control and HOXA9-knockdown SKOV3ip
cells were seeded as single cell suspensions onto con-
fluent monolayers of normal human omental mesothe-
lial cells. Attachment of SKOV3ip cells to mesothelial
cells was assayed at 1 h after seeding during which
time no significant change in cell aggregation or sur-
vival occurred. The numbers of HOXA9-knockdown
SKOV3ip cells that bound to mesothelial cells were
significantly lower than the numbers of bound control
SKOV3ip cells (P < 0.001) [Figures 2E,F]. To evaluate
the effect of HOXA9 on the migratory potential of
EOC cells independently of its effects on cell aggrega-
tion and mesothelial attachment, we assayed migration
of EOC cells that were seeded as single cell suspen-
sions into transwell chambers. As compared to control
SKOV3ip cells, HOXA9-knockdown SKOV3ip cells
exhibited significantly reduced migration (P < 0.001)
[Figure 2G]. These findings indicate that HOXA9
expression in EOC cells stimulates EOC-mesothelial
cell interactions and EOC cell migration, and that
these stimulatory effects are independent of its effect
on EOC cell aggregation and survival.
HOXA9 binds the CDH3 promoter and induces P-cadherin
expression
The classical cadherin P-cadherin has been reported to
be induced during early stages of EOC progression and
to promote EOC cell migration [11-13]. We recently
identified that P-cadherin also facilitates aggregation of
floating EOC cells, prevents anoikis and mediates the
attachment of EOC cells to peritoneal mesothelial
cells [14]. Because HOXA9 is a transcription factor,
we investigated the possibility that HOXA9 induces
P-cadherin expression. P-cadherin levels were mark-
edly reduced when HOXA9 was knocked-down in
SKOV3ip cells [Figure 3A]. Quantification of this pro-
tein down-regulation is shown in Additional file 2:
Figure S2A. The down-regulation of P-cadherin was
confirmed by quantitative reverse transcription PCR
(qRT-PCR) analysis of transcript levels of CDH3, the
gene encoding P-cadherin [Figure 3B]. Knockdown
of HOXA9 in SKOV3ip cells did not down-regulatelevels of other classical cadherins [Figure 3A]. SKO-
V3ip is an aggressive subclone that originally derived
from the parental SKOV3 cell line (SKOV3-Par) [15].
In contrast to SKOV3ip cells, SKOV3-Par cells did not
endogenously express HOXA9 or P-cadherin [Figure 3A].
Stable expression of HOXA9 in SKOV3-Par cells induced
P-cadherin expression at the protein and mRNA levels
[Figures 3A,B]. The Cancer Genome Atlas (TCGA)
dataset is the largest compilation of gene expression
data of clinical specimens of EOC. To determine whether
P-cadherin expression is elevated in clinical specimens
of EOC that highly express HOXA9, we stratified EOC
cases in the TCGA dataset (n = 567 cases) into quartile
sub-groups according to the levels of HOXA9 tran-
scripts of tumors. As shown in Figure 3C, levels of
CDH3 transcripts were found to be significantly higher
in HOXA9-High tumors (upper quartile sub-group) than
in HOXA9-Low tumors (lower quartile sub-group) (P =
0.011). Two putative consensus HOXA9-binding sites were
identified in the CDH3 promoter at 1.8 kb (site A) and
at 2.1 kb (site B) upstream of the transcription start site
[Figure 3D]. Binding of endogenous HOXA9 to both sites
was detected by chromatin immunoprecipitation (IP) assays
in control SKOV3ip cells, but no binding was detected in
HOXA9-knockdown SKOV3ip cells [Figure 3D]. These
findings indicate that HOXA9 induces P-cadherin ex-
pression and that the CDH3 gene is a transcriptional
target of HOXA9.
P-cadherin inhibition abrogates the stimulatory effects of
HOXA9 on EOC cell aggregation, implantation and
migration
To determine whether HOXA9 promotes EOC cell
aggregation, implantation and migration by inducing
P-cadherin expression, we evaluated the effects of inhi-
biting P-cadherin in EOC cells that expressed HOXA9.
P-cadherin levels that were induced by enforced HOXA9
expression in SKOV3-Par cells were knocked-down by
shRNAs targeting two different sites within the CDH3
gene (shPCAD-A, shPCAD-B) [Figure 4A]. Quantifica-
tion of this knockdown is shown in Additional file 2:
Figure S2B. Knockdown of P-cadherin in HOXA9+
SKOV3-Par cells reduced cell aggregation [Figure 4B].
Cell death in HOXA9+ SKOV3-Par cells was signifi-
cantly increased when P-cadherin was knocked-down
(P < 0.001) [Figures 4C,D]. To confirm our findings,
we evaluated the effects of inhibiting P-cadherin by a
neutralizing antibody (Ab). Treatment of suspension
cultures of HOXA9+ SKOV3-Par cells with P-cadherin
Ab inhibited cell aggregation and increased cell death,
as compared to cells that were treated with control IgG
[Additional file 3: Figure S3A,B]. In addition, knock-
down of P-cadherin in HOXA9+ SKOV3-Par cells
significantly reduced the ability of these tumor cells to
Figure 3 HOXA9 induces P-cadherin expression in EOC cells.
(A) Western blot analysis of HOXA9 and cadherin levels in control
and HOXA9-knockdown SKOV3ip lines and in vector-control and
HOXA9-transfected SKOV3-Par lines. The 34 kD band corresponding
to HOXA9 is indicated by an arrow. (B) qRT-PCR analysis of relative
CDH3 mRNA levels in SKOV3ip and SKOV3-Par lines. Significance
of differences in CDH3 mRNA levels was evaluated by Student
t-test. (C) EOC cases from the TCGA Project (n = 567) were stratified
according to HOXA9 expression in tumors, where HOXA9 mRNA levels
were defined as High (≥ upper quartile) and Low (≤ lower quartile).
Significance of differences in CDH3 mRNA levels (log2 scale) between
upper and lower quartile sub-groups was evaluated by Mann–Whitney
U-test. (D) Schematic representation of the human CDH3 promoter
showing locations of the two HOXA9-binding sites (site A:
5′-TCATTTAAAAC-3′ and site B: 5′-TAATTTATTTAATAC-3′). Binding
of endogenous HOXA9 in control SKOV3ip cells to these sites was
detected by chromatin IP. Negative controls included IP using
cells expressing HOXA9 shRNA (shA9-B) and IP with IgG. GAPDH
was amplified as an irrelevant gene control.
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(P < 0.001) [Figure 4D]. Together, these observations
indicate that the stimulatory effects of HOXA9 on
aggregation and survival of floating EOC cells, meso-
thelial attachment and EOC cell migration are largely
mediated by its induction of P-cadherin expression.
Stimulatory effects of HOXA9 on EOC cell aggregation,
implantation and migration are recapitulated by
P-cadherin in vitro and in vivo
In converse experiments, we evaluated whether the
stimulatory effects of HOXA9 on EOC cell aggrega-
tion, implantation and migration can be restored when
P-cadherin is reconstituted in EOC cells in which HOXA9
is inhibited. CDH3 cDNA was stably expressed in
HOXA9-knockdown SKOV3ip cells (shA9-B + PCAD)
to restore the level of P-cadherin that was similar to
the endogenous P-cadherin level in HOXA9+ control
(non-targeting) SKOV3ip cells [Figure 5A, Additional
file 2: Figure S2C]. Reconstitution of P-cadherin in
HOXA9-knockdown SKOV3ip cells markedly increased
cell aggregation and significantly decreased cell death in
suspension cultures (P < 0.001) [Figures 5B-D]. Recon-
stitution of P-cadherin also increased the ability of
HOXA9-knockdown SKOV3ip cells to attach to meso-
thelial monolayers and to migrate in in vitro assays
[Figure 5D].
To confirm the findings of our in vitro studies, we
firstly evaluated anoikis in floating EOC cells in short-
term in vivo assays. Based on our prior experience
using i.p. xenograft models derived from SKOV3ip
cells [10,14], the earliest time-point at which solid
peritoneal implants can be detected in mice is approxi-
mately 10 days following tumor cell inoculation. To
assay anoikis in floating EOC cells prior to implant-
ation, groups of mice were inoculated with equivalent
Figure 5 Reconstitution of P-cadherin in HOXA9-knockdown EOC cells restores the stimulatory effects of HOXA9 on cell survival,
implantation and migration in vitro. (A) Western blot analysis of P-cadherin levels in HOXA9+ control SKOV3ip cells (non-targeting),
HOXA9-knockdown SKOV3ip cells (shA9-B) and HOXA9-knockdown SKOV3ip cells that stably expressed P-cadherin (shA9-B + PCAD). (B) Morphology
of SKOV3ip cells following incubation as suspension cultures in polyHEMA-coated plates for 3 days. Bar, 100 μm. (C) Evaluation of cell death in
suspension cultures by flow cytometric analysis of 7AAD staining. (D) Evaluation of cell death by ELISA in suspension cultures of SKOV3ip cells,
attachment of SKOV3ip cells to confluent mesothelial cell monolayers, and migration of SKOV3ip cells. Shown in D are mean + sd values of
three independent assays.
Figure 4 Inhibition of P-cadherin in HOXA9-overexpressing EOC cells abrogates the stimulatory effects of HOXA9 on cell aggregation,
survival, implantation and migration. (A) Western blot analysis of P-cadherin levels in vector-control and HOXA9-transfected SKOV3-Par lines,
and in HOXA9-transfected SKOV3-Par lines that stably expressed non-targeting shRNA and shRNAs targeting two different sites within the CDH3
gene (shPCAD-A, shPCAD-B). (B,C) Cells of SKOV3-Par lines were incubated as suspension cultures in polyHEMA-coated plates for 3 days. (B) Cell
morphology viewed by phase-contrast light microscopy. Bar, 50 μm. (C) Evaluation of cell death by flow cytometric analysis of 7AAD staining.
(D) Evaluation of cell death by ELISA in suspension cultures of SKOV3-Par cells, attachment of SKOV3-Par cells to confluent mesothelial cell
monolayers, and migration of SKOV3-Par cells were assayed as described in Figures 2D, E and G, respectively. Shown in D are mean + sd values
of three independent assays.
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SKOV3ip cells. At 3 days thereafter, GFP-expressing EOC
cells in the peritoneal fluid were evaluated for cell death.
The proportion of floating EOC cells that exhibited cell
death in the shA9-B + PCAD model was markedly lower
than that in the shA9-B model and similar to that in the
control model [Figure 6A]. The numbers of implants thatFigure 6 Reconstitution of P-cadherin in HOXA9-knockdown EOC cell
implantation and migration in vivo. Female nude mice were inoculated i
and HOXA9-knockdown (shA9-B) SKOV3ip lines and HOXA9-knockdown SKOV
were sacrificed at 3 days following tumor cell inoculation. Floating cells in
death within the gated population of GFP+ tumor cells was evaluated by flow
3 weeks following tumor cell inoculation. (B) Representative examples o
peritoneal cavity wall as viewed by fluorescence microscopy. Bar, 1 mm.
five random 25 mm2 fields per mouse. (C) Representative examples of H
1 mm. Numbers of mesenteric implants were counted in three random
sections of diaphragmatic implants. Bar 100 μm.subsequently developed on the peritoneal cavity wall in
the shA9-B + PCAD group were significantly higher than
the numbers of implants in the shA9-B group (P < 0.01)
and almost equivalent to the numbers of implants in the
control group [Figure 6B]. Similar results were obtained
when we evaluated the numbers of mesenteric implants
in these groups of mice [Figure 6C]. Tumor implants thats restores the stimulatory effects of HOXA9 on cell survival,
.p. with equivalent numbers (2 × 106) of cells of control (non-targeting)
3ip cells that stably expressed P-cadherin (shA9-B + PCAD). In (A), mice
the peritoneal cavity were collected and stained with 7AAD. Cell
cytometric analysis of 7AAD staining. In (B-D), mice were analyzed at
f GFP-expressing tumor implants (shown in green) attached to the
Numbers of implants on the peritoneal cavity wall were counted in
E-stained sections of bowel tissues with mesenteric implants. Bar,
1 cm2 fields per mouse. (D) Representative examples of HE-stained
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diaphragm, bowel serosa and cavity wall were found to
be as invasive as control tumors and to exhibit greater
invasive depth than implants that derived from shA9-B
cells and formed at the same sites [Figure 6D; Additional
file 1: Figures S1A-C]. Together, our findings indicate
that HOXA9 promotes the aggregation and survival of
floating EOC cells and also the peritoneal attachment
and invasiveness of EOC cells, and that these stimula-
tory effects of HOXA9 are largely due to its induction
of P-cadherin expression.
Discussion
Substantial evidence indicates that aberrations in sig-
naling pathways that control normal developmental
patterning play pivotal roles in driving tumorigenesis
[16-18]. Homeoproteins comprise another important
class of patterning regulators and have been increas-
ingly found to be aberrantly expressed in a variety of
cancers [6,7]. Several homeoproteins promote tumor
cell proliferation by deregulating transcription of genes
that control cell cycle progression and autocrine
growth-stimulatory pathways [19-21]. There is also
evidence that some homeoproteins promote metastasis.
For example, SIX1 induces epithelial-to-mesenchymal
transition (EMT) in breast cancer cells by activating
transcription of the gene encoding the TGF-β type I
receptor [22] and promotes metastasis of rhabdomyo-
sarcoma by inducing expression of the cytoskeletal pro-
tein ezrin [23]. Both normal patterning and tumor
progression involve dynamic changes in homotypic and
heterotypic cellular interactions, but surprisingly only
few genes that control cell adhesion have been identi-
fied as homeoprotein targets [24,25]. We previously
identified that high HOXA9 expression is strongly asso-
ciated with poor overall survival in EOC patients and
promotes tumor progression in EOC xenograft models
[10]. The findings of this present study indicate that the
CDH3 gene which encodes P-cadherin is a transcrip-
tional target of HOXA9 and that HOXA9 promotes
both homotypic and heterotypic cell interactions that
facilitate intraperitoneal dissemination of EOC through
its induction of P-cadherin.
The propensity for intraperitoneal ‘seeding’ is a hall-
mark of EOC and depends on adaptation by EOC cells
to two dynamic changes in their microenvironment. The
first change occurs when EOC cells are exfoliated and
transported by the flow of the peritoneal fluid. It is
widely thought that aggregation enables floating EOC
cells to escape anoikis [3,4], but the mechanisms that
facilitate this aggregation are poorly understood. The
present study indicates that HOXA9 promotes aggrega-
tion of floating EOC cells by inducing expression of
P-cadherin. Inhibiting P-cadherin in HOXA9+ EOC cellsabolished the stimulatory effect of HOXA9 on aggre-
gation, whereas aggregation was almost completely
restored when P-cadherin was reconstituted in EOC
cells in which HOXA9 was inhibited. HOXA9 had little
effect on levels of other classical cadherins, but it is
not possible to exclude the possibility that HOXA9
might also promote tumor cell aggregation by inducing
expression of other types of adhesion molecules. The
classical cadherins have well-characterized functions in
facilitating homotypic cell adhesion [26,27]. The sig-
nificance of P-cadherin in mediating aggregation of
floating EOC cells is supported by our recent study in
which we demonstrated that inhibiting P-cadherin
reduces aggregation of ascitic EOC cells in xenograft
models [14]. High expression of P-cadherin has been
found to be associated with poor overall survival of
EOC patients [12]. A study by Patel and colleagues
identified that P-cadherin is the predominant type of
cadherin expressed in tumor cells in the peritoneal
fluid of EOC patients [11]. Sivertsen and colleagues
reported that P-cadherin is frequently expressed in
effusion specimens of EOC patients (51 of 53 cases),
but also found that E-cadherin and N-cadherin are
expressed at similar frequency [28]. There is discordance
in the literature regarding the expression of E-cadherin
and N-cadherin in effusion specimens of EOC patients.
Two studies have reported that levels of E-cadherin and
N-cadherin are decreased in effusions as compared to
solid tumors [11,29], whereas a third study identified
that E-cadherin levels were higher in effusions than in
matching primary solid tumors [30].
Although it is widely thought that aggregation enables
floating tumor cells to escape anoikis, the function of
cadherins in anoikis appears to be cell-specific. Inhib-
ition of E-cadherin increases anoikis sensitivity in Ewing
sarcoma cells [31], but increases anoikis resistance in
mammary epithelial cells [32]. Our recent studies sup-
port the notion that P-cadherin primarily inhibits anoikis
in EOC cells by promoting cell aggregation. Inhibition of
P-cadherin increased cell death in suspension cultures
but not in adherent cultures of EOC cells, and increased
cell death in ascitic EOC cells but not in solid tumor
xenografts [14]. The possibility that P-cadherin might
promote cell survival independently of cell aggregation
cannot be excluded. Cell adhesion is facilitated by in-
teractions between the extracellular domains of cad-
herin molecules on adjacent cells [26]. Intracellular
signal transduction triggered by P-cadherin involves
activation of Rac1 and Cdc42 Rho GTPases [33], but it
has been found that Rac1 and Cdc42 activation alone
does not fully account for the ability of P-cadherin
to suppress anoikis [14]. There is evidence that EMT
confers anoikis resistance in some cell types [32]. How-
ever, we have found that P-cadherin does not alter
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EOC cells [14]. We also cannot exclude the possibility
that HOXA9 inhibit anoikis by a mechanism that is
independent of P-cadherin. Because TGF-β signaling
induces EMT [34] and HOXA9 induces TGF-β2 ex-
pression in EOC cells [10], HOXA9 might inhibit anoikis
by promoting EMT. However, we found that HOXA9
neither represses E-cadherin expression [Figure 3A] nor
alters expression of EMT-promoting transcription factors
in EOC cells, including those that are induced by TGF-β
signaling [10]. Autocrine TGF-β signaling appears to be
impaired in EOC cells that express HOXA9 [10] and this
impairment could stem from the ability of HOXA9 to
block TGF-β-induced Smad-dependent transcription [35].
Collectively, these findings strongly suggest that the ability
of HOXA9 to inhibit anoikis in EOC cells is largely attrib-
utable to its induction of P-cadherin and the facilitation of
EOC cell aggregation by P-cadherin.
The second important rate-limiting step in the pro-
gression of EOC is the implantation of floating tumor
cells on to peritoneal surfaces. Interactions of EOC
cells with peritoneal mesothelial cells and/or the sub-
mesothelial extracellular matrix are mediated by vari-
ous cell surface molecules including CD44 and several
integrins [36,37]. We previously identified that HOXA10,
a homeoprotein that is expressed in a subset of EOCs, can
promote interactions between EOC cells and peritoneal
mesothelial cells by inducing expression of αvβ3 integrin
[38]. The notion that P-cadherin facilitates tumor-
peritoneum interactions is supported by findings that
P-cadherin is frequently expressed in malignant periton-
eal effusions of EOC patients and is the most predominant
type of cadherin in normal peritoneal tissues [11,28,39].
The findings of the present study indicate that the ability
of HOXA9 to promote interactions between EOC cells
and peritoneal mesothelial cells is primarily mediated
by its induction of P-cadherin. Inhibiting P-cadherin in
HOXA9+ EOC cells abrogated the stimulatory effect of
HOXA9 on mesothelial cell attachment, and reconstitu-
tion of P-cadherin in HOXA9-knockdown cells restored
attachment capability. Our work also demonstrates that
HOXA9 promotes migratory potential of EOC cells via
its induction of P-cadherin. The function of P-cadherin
in cell migration varies depending on the type of cell.
It has been reported that P-cadherin inhibits migration
of melanoma and oral squamous cell carcinoma cells
[40,41], but promotes migration of pancreatic and blad-
der cancer cells [33,42]. Our findings support prior
reports that P-cadherin stimulates migratory potential
of EOC cells [13,14].
Because the precise mechanism of HOXA9 in con-
trolling female reproductive development is not
known, it is unclear how its induction of P-cadherin in
EOC might be related to its normal developmentalfunction. Cadherin-mediated cell adhesion is essential
for maintaining the structure and function of repro-
ductive tissues [43], but mice with targeted disruption
of the Cdh3 or Hoxa9 genes are fertile [44,45]. The
mechanisms that induce HOXA9 expression in EOC
are also poorly understood. One possible mechanism is
deregulated promoter methylation. HOXA9 promoter
methylation has been detected at significantly lower
frequency in advanced-stage EOC than in early-stage
tumors [46]. Another possible mechanism is histone
modification. Polycomb group (PcG) proteins form
complexes that dynamically alter chromatin structure
by modifying specific residues in histone tails and PcG-
mediated repression is a principal mechanism by which
HOX gene expression is tightly regulated during devel-
opment [47]. AKT signaling has been reported to sup-
press the histone methyltransferase activity of the PcG
protein EZH2 [48], and is frequently activated in high-
grade, advanced-stage EOCs [49]. It is therefore pos-
sible that AKT activation in EOC derepresses HOXA9
expression by inhibiting EZH2 activity. Interestingly,
HOXA9 is not endogenously expressed in the parental
SKOV3 cell line but in the aggressive subclone SKOV3ip
[Figure 3A]. The expression of HOXA9 in SKOV3ip cells
might be attributable to SKOV3ip cells having higher
ERBB2 levels than the parental SKOV3 cells [15].Conclusion
The present study supports increasing evidence of the
functional significance of homeoproteins in dictating
the clinical behavior of tumors through controlling
transcription of distinct sets of target genes. Because
homeoproteins are transcription factors and share
tracts of homology, it is challenging to therapeutically
target these proteins. However, elucidating the mecha-
nisms of homeoproteins and their downstream effec-
tors in tumors can yield important insights into more
effective therapeutic strategies. Inhibiting P-cadherin is
particularly promising as a human monoclonal Ab to
P-cadherin has been developed and is undergoing clin-
ical trials [50].Methods
Abs and plasmids
Abs to HOXA9 were purchased from Millipore (for
Western blot) and Santa Cruz Biotechnology (for chro-
matin IP). Abs to P-cadherin were purchased from BD Bio-
sciences (for Western blot) and Abcam (for neutralization).
Other Abs were as follows: E-cadherin (Invitrogen),
N-cadherin, active caspase-3 (BD Biosciences), actin,
secondary Abs (Sigma-Aldrich). HOXA9 cDNA was
provided by Corey Largman (Veterans Affairs Medical
Center, San Francisco). CDH3 cDNA and pGFP-V-RS
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shRNAs were purchased from OriGene Technologies.
Cell culture and transfection
SKOV3ip cell lines that stably express non-targeting
and HOXA9 shRNAs have been previously described
[10]. The parental SKOV3 cell line was purchased from
American Type Culture Collection. Cell lines were
authenticated by short tandem repeat analysis performed
by the MD Anderson Cancer Center Characterized Cell
Line Core Facility. SKOV3ip and SKOV3 cells were
cultured in McCoys 5A medium (Invitrogen) supple-
mented with 10% FBS and penicillin-streptomycin. Cells
were transfected by using Lipofectamine 2000 reagent
(Invitrogen) and selected by the addition of puromycin
(0.5 μg/ml). Primary cultures of normal human omental
mesothelial cells have been previously described [51]
and were provided by Ernst Lengyel (University of Chicago,
Chicago, IL).
Western blot and qRT-PCR analyses
Cell lysates were prepared by using M-PER buffer
(Pierce Biotechnology), separated by SDS-PAGE and
transferred to polyvinylidene difluoride membranes (GE
Healthcare). CDH3 transcripts were analyzed by using
SYBR®Green qPCR Master Mix (SABiosciences) and the
following primers: forward: 5′-CAGGTGCTGAACATC
ACGGACA-3′, reverse: 5′-CTTCAGGGACAAGACCA
CTGTG-3′. RPL32 transcript levels were used as
controls for normalization and were detected by using
the following primers: forward: 5′-ACAAAGCACA
TGCTGCCCAGTG-3′ reverse: 5′- TTCCACGATGG
CTTTGCGGTTC-3′.
Chromatin IP
Chromatin IP assays were performed by using the
EZ-ChIP Assay kit (Millipore). Sheared chromatin was
incubated overnight with 1 μg of HOXA9 Ab. DNA was
purified from precipitated complexes. Fragments of the
human CDH3 promoter were amplified by using the fol-
lowing primers: for Site A (150 bp), forward: 5′-CCCCCA
CCCTCGCAACGCAAGCAA-3′, reverse: 5′-TGGGATT
ACAGGCGTGAGAAACG-3′; for Site B (104 bp),
forward: 5′-GCTGTGTGCCAGATATGATGTTTAG-3′,
reverse: 5′-CTGTCAAATGGGGCTGTTATGATC-3′. A
166 bp fragment of the GAPDH gene was amplified as an




EOC cells were seeded in 96-well plates (1 × 104 cells per
well) that were coated with polyHEMA (Sigma-Aldrich)
to block cell attachment to substratum as previouslydescribed [38]. Where indicated, EOC cells were incu-
bated with neutralizing P-cadherin Ab or with control
IgG at a final concentration of 10 μg/ml. At 3 days there-
after, cell morphology was viewed by phase-contrast light
microscopy. Cells were evaluated for cell death by staining
with 7AAD (Sigma-Aldrich) and with Ab to active caspase-
3. Staining was detected by flow cytometry (FACS Calibur,
BD Biosciences). Cell death was also evaluated by assaying
mono- and oligo- nucleosomes in cell lysates by using the
Cell Death Detection ELISA kit (Roche). Three independ-
ent experiments were performed for each assay.
Cell attachment assays
Single cell suspensions of GFP-expressing EOC cells were
seeded in 96-well plates (1.5 × 104 per well) containing
confluent monolayers of normal omental mesothelial cells
as previously described [38]. At 1 hr after seeding of EOC
cells, wells were washed with culture medium to remove
unattached EOC cells. Attached EOC cells were viewed by
fluorescence microscopy using a fluorescein filter. Three
independent experiments were performed in which
attached cells were counted in three random 100×
microscopic fields in each experiment.
Cell migration assays
EOC cells were seeded as single cell suspensions in the
upper chamber of 24-well transwell chambers (BD
Biosciences) (5 × 104 cells per well). At 6 h thereafter,
migrating cells were stained with Giemsa solution.
Three independent experiments were performed in
which migrating cells were counted in three random
100x microscopic fields in each experiment.
Mouse i.p. xenograft studies
Four-week-old female nude mice (purchased from the Na-
tional Cancer Institute, Frederick, MD) were inoculated i.
p. with 2 × 106 cells of GFP-expressing EOC lines (n = 5
mice per group). Mice were euthanized by CO2 asphyxi-
ation at time points indicated in the figure legends.
GFP-expressing tumor implants were visualized under a
Leica MZML III stereomicroscope equipped with a mer-
cury lamp power supply and GFP filter set. Formalin-
fixed, paraffin-embedded tissue sections were stained with
hematoxylin-eosin (HE) and analyzed under a light micro-
scope. Invasive depth of implants was measured using a
stage micrometer slide in five random microscopic fields
of tissue sections of each mouse at the magnifications
indicated in the figure legends. Floating cells were col-
lected from peritoneal fluid, stained with Hoechst dye and
viewed by fluorescence microscopy. Floating cells were
also stained with 7AAD and cell clusters gently disaggre-
gated by passing through 35 μm nylon mesh. Immediately
thereafter, 7AAD staining was analyzed by flow cytometry
within the gated population of GFP + tumor cells.
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Gene expression data of EOC cases from the TCGA pro-
ject (n = 567) were downloaded from the TCGA data
portal site (http://tcga-data.nci.nih.gov/tcga/). Where there
were multiple probe sets for an individual gene, the mean
value for the given gene for each case was used. Patients
were stratified according to the level of HOXA9 expression
in tumors, where HOXA9 transcript levels were defined as
High (≥ upper quartile) and Low (≤ lower quartile) as pre-
viously described [10].
Statistical analysis
Statistical analysis was performed by using STATISTICA6
software (StatSoft Inc.). Statistical significance of data of
in vitro and in vivo assays was assessed by unpaired two-
tailed Student’s t-test. Data represent mean ± s.d. Signifi-
cance of differences in gene expression between groups of
patients was assessed by Mann–Whitney U-test. P values
of < 0.05 were considered significant.
Additional files
Additional file 1: Figure S1. Invasiveness of EOC cells in i.p. xenograft
models. Female nude mice (n=5 per group) were inoculated i.p. with
equivalent numbers of cells (2 × 106) of SKOV3ip lines and sacrificed at 3
weeks thereafter. Invasive depth of implants on the bowel, diaphragm and
peritoneal cavity wall was measured in five random microscopic fields of
HE-stained tissue sections of each of these sites in each mouse. An average
invasive depth was calculated for each site of each mouse. (A) Depth of
superficial bowel serosa invasion (evaluated at 200× magnification) and
representative examples of HE-stained sections. Bar, 50 μm. (B) Depth of
invasion of diaphragmatic implants into adjacent muscle (evaluated at
100x magnification). Representative examples of HE-stained sections of
diaphragmatic implants are shown in Figure 1D. (C) Invasive depth of
implants on the peritoneal cavity wall (evaluated at 100× magnification)
and representative examples of HE-stained sections. Bar, 100 μm.
Additional file 2: Figure S2. Quantification of protein levels. Protein
levels were evaluated by measuring intensity of bands on Western blots
shown in Figures 3A, 4A and 5A using the TINA 20 program (Raytest).
(A) Levels of an individual protein in SKOV3ip lines transfected with
non-targeting and HOXA9 shRNAs are expressed relative to its level in
the empty vector control SKOV3ip line. Levels of an individual protein in
the HOXA9-transfected SKOV3-Par line are expressed relative to its level
in the empty vector control SKOV3-Par line. (B) Levels of P-cadherin in
HOXA9-transfected SKOV3-Par lines that were co-transfected with no
shRNA, non-targeting shRNA or CDH3 shRNAs are expressed relative to
its level in the empty vector control SKOV3-Par line. (C) Levels of P-
cadherin in HOXA9-knockdown SKOV3ip cells and HOXA9-knockdown
SKOV3ip cells that stably expressed P-cadherin are expressed relative to
its level in SKOV3ip cells expressing non-targeting shRNA.
Additional file 3: Figure S3. Effects of P-cadherin Ab on
HOXA9-overexpressing EOC cells. Cells of vector-control and
HOXA9-transfected SKOV3-Par lines were incubated as suspension
cultures in polyHEMA-coated plates for 3 days with the addition of
neutralizing P-cadherin Ab or control IgG. (A) Cell morphology
viewed by phase-contrast microscopy. Bar 50 μm. (B) Cell death was
evaluated by assaying mono- and oligo- nucleosomes in cell lysates
by ELISA. Shown are mean + sd values of three independent experiments.
Abbrevations
7AAD: 7-amino actinomycin D; Ab: Antibody; EOC: Epithelial ovarian cancer;
ECAD: E-cadherin; HE: Hematoxylin-eosin; NCAD: N-cadherin; PCAD: P-cadherin; PcG: Polycomb group; PolyHEMA: Poly (2-hydroxyethyl
methacrylate); shRNAs: Short hairpin RNAs; TGF: Transforming growth factor.
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